文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一名年轻乳腺癌患者的新发从头突变：病例报告

A New de novo Mutation in a Young Breast Cancer Patient: A Case Report.

作者信息

Scherz Amina, Stoll Susanna, Rothlisberger Benno, Rabaglio Manuela

机构信息

Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Department of Medical Oncology, University Hospital and Stadtspital Triemli, Zurich, Switzerland.

出版信息

Appl Clin Genet. 2023 May 11;16:83-87. doi: 10.2147/TACG.S405120. eCollection 2023.

DOI:10.2147/TACG.S405120
PMID:37197323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10184889/
Abstract

BACKGROUND: and genes represent the most investigated breast and ovarian cancer predisposition genes. Ten cases of pathogenic de novo variations and six cases of pathogenic de novo variation have been reported at present. Here, we report a new case of a de novo gene mutation. CASE PRESENTATION: A 30-year-old woman with no health issues and no family history for hereditary breast and ovarian cancer was diagnosed with a hormone receptor positive/HER2 negative invasive breast cancer. Genetic testing revealed a pathogenic variant in (c.4065_4068delTCAA) which was not found in her parents or sister. CONCLUSION: We report a new case of de novo mutation, confirmed by repeated germline testing of the index patient and her parents. The published de novo mutation rate is low. This is probably due - in part - to the strict testing criteria.

摘要

背景：BRCA1和BRCA2基因是研究最多的乳腺癌和卵巢癌易感基因。目前已报道了10例致病性新发BRCA1变异病例和6例致病性新发BRCA2变异病例。在此，我们报告1例新的BRCA2基因新发突变病例。 病例介绍：一名30岁女性，无健康问题，无遗传性乳腺癌和卵巢癌家族史，被诊断为激素受体阳性/人表皮生长因子受体2阴性浸润性乳腺癌。基因检测发现BRCA2基因存在一个致病性变异（c.4065_4068delTCAA），其父母和姐姐均未检测到该变异。 结论：我们报告了1例新的BRCA2基因新发突变病例，通过对先证者及其父母进行反复的种系检测得以证实。已发表的BRCA2基因新发突变率较低。这可能部分归因于严格的检测标准。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12c7/10184889/d5119ac09ff2/TACG-16-83-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12c7/10184889/d5119ac09ff2/TACG-16-83-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12c7/10184889/d5119ac09ff2/TACG-16-83-g0001.jpg

相似文献

[1]
A New de novo Mutation in a Young Breast Cancer Patient: A Case Report.

Appl Clin Genet. 2023-5-11

[2]
A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer.

Fam Cancer. 2011-6

[3]
Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.

Oncogene. 2016-3-10

[4]
A de Novo BRCA1 Pathogenic Variant in a 29-Year-Old Woman with Triple-Negative Breast Cancer.

Breast Care (Basel). 2023-10

[5]
Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.

Breast Cancer Res Treat. 2011-5-7

[6]
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.

Oncologist. 1996

[7]
De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer.

J Med Genet. 2001-2

[8]
Case report: de novo BRCA2 gene mutation in a 35-year-old woman with breast cancer.

Clin Genet. 2009-10-1

[9]

2008-2

[10]
[Hereditary breast carcinomas pathologist's perspective].

Ann Pathol. 2020-4

引用本文的文献

[1]
Case Report: and loss in a young man with primary cutaneous extraskeletal osteosarcoma.

Front Oncol. 2025-3-4

[2]
Novel De Novo Variant in an Early-Onset Ovarian Cancer Reveals a Unique Tumor Evolution Pathway.

Int J Mol Sci. 2025-3-5

[3]
A de novo germline pathogenic BRCA1 variant identified following an osteosarcoma pangenomic molecular analysis.

Fam Cancer. 2024-11

[4]
Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition?

Int J Mol Sci. 2023-11-30

本文引用的文献

[1]
Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.

Int J Cancer. 2022-8-1

[2]
A new case of "de novo" BRCA1 mutation in a patient with early-onset breast cancer.

Clin Case Rep. 2017-1-28

[3]
Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.

Oncogene. 2016-3-10

[4]
A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening.

J Med Genet. 2014-2

[5]
A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands.

Clin Genet. 2014-4

[6]
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

J Natl Cancer Inst. 2013-4-29

[7]
A germline mosaic BRCA1 exon deletion in a woman with bilateral basal-like breast cancer.

Clin Genet. 2013-9

[8]
A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.

BMC Med Genet. 2011-10-11

[9]
Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.

Breast Cancer Res Treat. 2011-5-7

[10]
A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer.

Fam Cancer. 2011-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索